DiaMedica Therapeutics Inc.
DMAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001401040
No open-market purchases or sales by DiaMedica Therapeutics Inc. insiders were filed in the last 90 days; 88 institutions reported holding it in 13F filings for Q2 2026, worth $87.8M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding DiaMedica Therapeutics Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 34 | 39 | +5 |
| Shares | 2.81M | 4.00M | +1.19M (+42.4%) |
| Value | $11.2M | $14.9M | +$3.65M (+32.5%) |
New holders (8)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Anson Funds Management LP | 130,070 | $485.0K | 0.07% |
| Millennium Management LLC | 22,249 | $83.0K | 0.00% |
| Dimensional Fund Advisors LP | 11,900 | $44.0K | 0.00% |
| UBS Group AG | 4,618 | $17.0K | 0.00% |
| TD Waterhouse Canada Inc. | 1,840 | $8.33K | 0.00% |
| Sandy Cove Advisors, LLC | 1,200 | $4.00K | 0.00% |
| Bank of America Corp | 3 | $0 | 0.00% |
| FinTrust Capital Advisors, LLC | 75 | $0 | 0.00% |
Sold out (3)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Barclays PLC | 4,616 | $19.0K |
| Gables Capital Management Inc. | 542 | $2.00K |
| Gerber Kawasaki Wealth & Investment Management | 197 | $0 |